ANGPTL6

Summary

ANGPTL6 (angiopoietin like 6, HGNC:23140) is a protein-coding gene on chromosome 19p13.2, encoding Angiopoietin-related protein 6 (Q8NI99). May play a role in the wound healing process.

Predicted to enable signaling receptor binding activity. Predicted to be involved in angiogenesis; blood coagulation; and cell differentiation. Located in collagen-containing extracellular matrix and extracellular exosome. Biomarker of gestational diabetes.

Source: NCBI Gene 83854 — RefSeq curated summary.

At a glance

• Gene–disease (curated): brain aneurysm (Strong, GenCC) — +1 more curated relationship
• GWAS associations: 2
• Clinical variants (ClinVar): 104 total
• Phenotypes (HPO): 15
• MANE Select transcript: NM_031917

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:23140
Approved symbol	ANGPTL6
Name	angiopoietin like 6
Location	19p13.2
Locus type	gene with protein product
Status	Approved
Aliases	ARP5, AGF
Ensembl gene	ENSG00000130812
Ensembl biotype	protein_coding
OMIM	609336
Entrez	83854

Gene structure

Transcript identifiers

Ensembl transcripts: 11 — 10 protein_coding, 1 retained_intron

ENST00000253109, ENST00000586910, ENST00000589181, ENST00000592641, ENST00000890998, ENST00000890999, ENST00000891000, ENST00000891001, ENST00000891002, ENST00000891003, ENST00000930867

RefSeq mRNA: 4 — MANE Select: NM_031917 NM_001321411, NM_001387347, NM_001387348, NM_031917

CCDS: CCDS12224

Canonical transcript exons

ENST00000253109 — 6 exons

Exon	Start	End
ENSE00001383912	10102568	10102678
ENSE00003979668	10094758	10094938
ENSE00003979669	10093693	10093880
ENSE00003979670	10092338	10092779
ENSE00003979672	10093349	10093619
ENSE00003979682	10095982	10096573

Expression profiles

Bgee: expression breadth ubiquitous, 153 present calls, max score 88.34.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.3940 / max 20.8603, expressed in 171 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
179066	0.2427	102
179067	0.0986	45
179068	0.0527	23

Top tissues by expression

252 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right lobe of liver	UBERON:0001114	88.34	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	86.85	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	83.38	gold quality
liver	UBERON:0002107	82.68	gold quality
cartilage tissue	UBERON:0002418	73.15	gold quality
granulocyte	CL:0000094	70.64	gold quality
tendon of biceps brachii	UBERON:0008188	70.20	gold quality
spleen	UBERON:0002106	68.88	gold quality
vermiform appendix	UBERON:0001154	67.01	gold quality
lymph node	UBERON:0000029	66.76	gold quality
small intestine Peyer’s patch	UBERON:0003454	64.41	gold quality
bone marrow cell	CL:0002092	64.19	silver quality
small intestine	UBERON:0002108	62.94	gold quality
blood	UBERON:0000178	61.50	gold quality
placenta	UBERON:0001987	61.50	gold quality
caecum	UBERON:0001153	61.21	gold quality
sperm	CL:0000019	61.17	gold quality
prefrontal cortex	UBERON:0000451	60.85	gold quality
ileal mucosa	UBERON:0000331	60.45	silver quality
jejunal mucosa	UBERON:0000399	60.43	silver quality
mucosa of transverse colon	UBERON:0004991	59.61	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	58.61	gold quality
tibia	UBERON:0000979	58.30	silver quality
stomach	UBERON:0000945	58.04	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	58.04	gold quality
body of stomach	UBERON:0001161	57.97	gold quality
leukocyte	CL:0000738	57.74	gold quality
duodenum	UBERON:0002114	57.40	gold quality
body of pancreas	UBERON:0001150	57.12	gold quality
monocyte	CL:0000576	56.98	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	1.45

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

21 targeting ANGPTL6, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-4648	99.91	67.00	710
HSA-MIR-7162-3P	99.89	68.16	1682
HSA-MIR-6783-3P	99.89	67.92	2059
HSA-MIR-6715A-3P	99.83	68.05	1473
HSA-MIR-4649-3P	99.56	66.90	1783
HSA-MIR-6887-5P	98.56	68.49	1295
HSA-MIR-6852-3P	98.54	67.60	1468
HSA-MIR-6795-5P	98.52	68.51	1277
HSA-MIR-7114-5P	98.51	67.87	1349
HSA-MIR-6827-5P	98.46	64.88	1256
HSA-MIR-1199-5P	98.44	66.51	829
HSA-MIR-6751-3P	98.44	66.35	835
HSA-MIR-5008-5P	98.42	65.87	1019
HSA-MIR-3670	97.88	64.39	763
HSA-MIR-556-5P	97.75	66.17	473
HSA-MIR-3909	97.55	66.78	887
HSA-MIR-194-3P	97.36	65.96	1027
HSA-MIR-134-3P	96.83	66.22	1001
HSA-MIR-4512	95.26	63.08	371
HSA-MIR-4523	85.64	61.16	64

Literature-anchored findings (GeneRIF, showing 24)

• findings suggest that AGF affects epidermal proliferation and thereby plays a role in the wound healing process (PMID:12871997)
• showed that AGF is a secreted protein, AGF directly promotes chemotactic activity of vascular endothelial cells, and AGF directly induces a permeability change in the local vasculature. (PMID:14764539)
• Our results strongly suggest that AGF is an integrin ligand as well as a mitogenic growth factor and theoretically participates in cutaneous wound healing in a more complex mechanism. (PMID:16806062)
• study of associations between ANGPTL6 polymorphisms and metabolic syndrome or related phenotypes in a French population (PMID:19447061)
• serum AGF levels were paradoxically increased in metabolic syndrome, in comparison with data from animal experiments and data on sex, age, and waist circumference (PMID:20673930)
• ANGPTL6 affects resting metabolic rate (RMR), significantly improves lipid profile and slightly improves insulin levels and insulin sensitivity, as well. (PMID:21460784)
• Serum AGF levels are significantly higher in subjects with polycystic ovary syndrome than those in the healthy control group. (PMID:22406517)
• Interaction between alpha6 integrin and E-cadherin drives liver metastasis of colorectal cancer cells through hepatic angiopoietin-like 6. (PMID:23070965)
• There are no significant differences in maternal Angptl6/ARP5 serum level between pre-eclamptic women and normally pregnant control women (PMID:23718665)
• In the second trimester, Angptl6 levels are higher in women with subsequent pregnancy-induced hypertension. (PMID:23905605)
• AGF concentrations is significantly higher in patients with type 2 diabetes as compared to controls. (PMID:25011017)
• Serum ANGPTL6 levels increased in patients with a hypothyroid status, and both TSH and free T4 levels are associated with ANGPLT6 levels, suggesting a possible association between thyroid function and ANGPTL6 levels. (PMID:26189599)
• ANGPTL6, S100A8 and S100A9 are overexpressed in skin of psoriasis patients versus zero expression in controls. (PMID:27698489)
• Data suggest that serum AGF levels are up-regulated in type 2 diabetic patients with lower extremity peripheral arterial disease according to disease severity; patients with highest serum AGF levels exhibit increased cardiovascular mortality and all-cause mortality. (PMID:27866700)
• Poor glycemic control in diabetes mellitus as reflected by higher serum HbA1c levels is associated with raised serum ANGPTL6 levels (PMID:29033485)
• rare coding variants in ANGPTL6 are causally related to familial forms of Intracranial aneurysms. (PMID:29304371)
• ANGPTL6 is an important driver gene of angiogenesis in AFPGC development (PMID:31146977)
• Investigating the Role of Myeloperoxidase and Angiopoietin-like Protein 6 in Obesity and Diabetes. (PMID:32277104)
• ANGPTL6 Genetic Variants Are an Underlying Cause of Familial Intracranial Aneurysms. (PMID:33106390)
• Angiopoietin-Like Growth Factor Involved in Leptin Signaling in the Hypothalamus. (PMID:33810547)
• Use of proteomics to identify mechanisms of hepatocellular carcinoma with the CYP2D6*10 polymorphism and identification of ANGPTL6 as a new diagnostic and prognostic biomarker. (PMID:34412629)
• Differential Proteomic Profiles of Coronary Serum Exosomes in Acute Myocardial Infarction Patients with or Without Diabetes Mellitus: ANGPTL6 Accelerates Regeneration of Endothelial Cells Treated with Rapamycin via MAPK Pathways. (PMID:35821539)
• Relationship of ANGPTL6 With Neonatal Glucose Homeostasis and Fat Mass Is Disrupted in Gestational Diabetic Pregnancies. (PMID:35876300)
• Associations of ANGPTL6, DOCK6, FABP1, and PCSK9 single-nucleotide variants with hypercholesterolemia in the Polish population: a cross-sectional study. (PMID:36601873)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	angptl6	ENSDARG00000020265
mus_musculus	Angptl6	ENSMUSG00000038742
rattus_norvegicus	Angptl6	ENSRNOG00000020603

Paralogs (25): TNC (ENSG00000041982), FCN1 (ENSG00000085265), ANGPT2 (ENSG00000091879), ANGPT4 (ENSG00000101280), FGL1 (ENSG00000104760), FN1 (ENSG00000115414), TNR (ENSG00000116147), ANGPTL1 (ENSG00000116194), TNN (ENSG00000120332), FGL2 (ENSG00000127951), FIBCD1 (ENSG00000130720), ANGPTL3 (ENSG00000132855), ANGPTL2 (ENSG00000136859), FCN3 (ENSG00000142748), FNDC7 (ENSG00000143107), ANGPT1 (ENSG00000154188), FCN2 (ENSG00000160339), MFAP4 (ENSG00000166482), ANGPTL4 (ENSG00000167772), TNXB (ENSG00000168477), FGG (ENSG00000171557), FGA (ENSG00000171560), FGB (ENSG00000171564), ANGPTL7 (ENSG00000171819), ANGPTL5 (ENSG00000187151)

Protein

Protein identifiers

Angiopoietin-related protein 6 — Q8NI99 (reviewed: Q8NI99)

Alternative names: Angiopoietin-like protein 6, Angiopoietin-related growth factor, Angiopoietin-related protein 5

All UniProt accessions (2): Q8NI99, K7EKF6

UniProt curated annotations — full annotation on UniProt →

Function. May play a role in the wound healing process. May promote epidermal proliferation, remodeling and regeneration. May promote the chemotactic activity of endothelial cells and induce neovascularization. May counteract high-fat diet-induced obesity and related insulin resistance through increased energy expenditure.

Subcellular location. Secreted.

RefSeq proteins (4): NP_001308340, NP_001374276, NP_001374277, NP_114123* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR002181	Fibrinogen_a/b/g_C_dom	Domain
IPR014716	Fibrinogen_a/b/g_C_1	Homologous_superfamily
IPR020837	Fibrinogen_CS	Conserved_site
IPR036056	Fibrinogen-like_C	Homologous_superfamily
IPR037579	FIB_ANG-like	Family

Pfam: PF00147

UniProt features (30 total): strand 12, helix 7, glycosylation site 2, disulfide bond 2, signal peptide 1, chain 1, domain 1, turn 1, region of interest 1, coiled-coil region 1, sequence conflict 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
6Y43	X-RAY DIFFRACTION	1.6

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8NI99-F1	76.03	0.44

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Disulfide bonds (2): 260–287, 410–423

Glycosylation sites (2): 58, 145

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 133 (showing top): GOCC_SECRETORY_GRANULE, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, GOBP_WOUND_HEALING, VART_KSHV_INFECTION_ANGIOGENIC_MARKERS_UP, GROSS_HYPOXIA_VIA_ELK3_DN, GOBP_BLOOD_VESSEL_MORPHOGENESIS, SCHAEFFER_PROSTATE_DEVELOPMENT_48HR_DN, GOBP_HEMOSTASIS, HAND1E47_01, GOMF_SIGNALING_RECEPTOR_BINDING, GOBP_REGULATION_OF_BODY_FLUID_LEVELS, GOBP_CIRCULATORY_SYSTEM_DEVELOPMENT, GOCC_SECRETORY_VESICLE, chr19p13, GOBP_TUBE_MORPHOGENESIS

GO Biological Process (3): angiogenesis (GO:0001525), blood coagulation (GO:0007596), cell differentiation (GO:0030154)

GO Molecular Function (1): signaling receptor binding (GO:0005102)

GO Cellular Component (5): obsolete extracellular space (GO:0005615), secretory granule (GO:0030141), extracellular matrix (GO:0031012), extracellular exosome (GO:0070062), extracellular region (GO:0005576)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
blood vessel morphogenesis	1
anatomical structure formation involved in morphogenesis	1
hemostasis	1
wound healing	1
coagulation	1
cellular developmental process	1
protein binding	1
endomembrane system	1
secretory vesicle	1
external encapsulating structure	1
extracellular vesicle	1
cellular anatomical structure	1

Protein interactions and networks

STRING

390 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ANGPTL6	CDH1	P12830	839
ANGPTL6	ITGA2B	P08514	669
ANGPTL6	ANGPTL8	Q6UXH0	660
ANGPTL6	LECT2	O14960	496
ANGPTL6	FGF21	Q9NSA1	479
ANGPTL6	SELENOP	P49908	476
ANGPTL6	AHSG	P02765	446
ANGPTL6	TIE1	P35590	402
ANGPTL6	VASH1	Q7L8A9	371
ANGPTL6	STC1	P52823	369
ANGPTL6	ENHO	Q6UWT2	360
ANGPTL6	HTATIP2	Q9BUP3	360
ANGPTL6	TNFSF15	O95150	359
ANGPTL6	TMEM116	Q8NCL8	351
ANGPTL6	GLG1	Q92896	350
ANGPTL6	AGA	P20933	350

IntAct

3 interactions, top by confidence:

A	B	Type	Score
STAT5A	FLOT1	psi-mi:“MI:0914”(association)	0.350
ATG16L1		psi-mi:“MI:0914”(association)	0.350

BioGRID (4): ANGPTL6 (Proximity Label-MS), ANGPTL6 (Affinity Capture-MS), ANGPTL6 (Affinity Capture-MS), ANGPTL6 (Two-hybrid)

ESM2 similar proteins: A2AV25, A5PJQ2, O35764, O43278, O43827, O70165, O95841, O95897, P02675, P02678, P04115, P12804, P14480, P30203, P33573, Q0P4P2, Q14314, Q1RMR1, Q24K15, Q29041, Q29042, Q29RY7, Q2KJ51, Q2TNK5, Q568Y7, Q5EA66, Q5FB95, Q5I2E5, Q5XK91, Q640P2, Q6AX44, Q6TMA8, Q8BM13, Q8IUK5, Q8K0E8, Q8N539, Q8NI99, Q8R0Z6, Q8R1Q3, Q91ZV7

Diamond homologs: A0A8J8, A2AV25, D8VNS7, D8VNS8, D8VNS9, D8VNT0, E2IYB3, E9PV24, O00602, O08538, O15123, O18920, O35460, O35462, O35608, O43827, O70165, O70497, O75636, O77802, O93526, O95841, P02671, P02675, P02676, P02678, P02679, P02680, P04115, P06399, P10039, P12799, P12804, P14448, P14480, P17634, P19477, P21520, P22105, P24821

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

104 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	91
Likely benign	6
Benign	4

Top pathogenic / likely-pathogenic (0)

SpliceAI

952 predictions. Top by Δscore:

Variant	Effect	Δscore
19:10093344:CTTA:C	donor_loss	1.0000
19:10093347:A:AC	donor_gain	1.0000
19:10093348:C:CC	donor_gain	1.0000
19:10093348:CCAG:C	donor_loss	1.0000
19:10094754:TTA:T	donor_loss	1.0000
19:10094755:TAC:T	donor_loss	1.0000
19:10094756:A:T	donor_loss	1.0000
19:10094756:AC:A	donor_gain	1.0000
19:10094757:CC:C	donor_gain	1.0000
19:10094757:CCCA:C	donor_gain	1.0000
19:10094940:T:A	acceptor_loss	1.0000
19:10106370:G:GT	donor_gain	1.0000
19:10106408:G:GT	donor_gain	1.0000
19:10106408:GGAGG:G	donor_gain	1.0000
19:10106409:G:T	donor_gain	1.0000
19:10106409:GAGG:G	donor_gain	1.0000
19:10106409:GAGGG:G	donor_gain	1.0000
19:10106410:A:T	donor_gain	1.0000
19:10106411:GG:G	donor_gain	1.0000
19:10106412:GG:G	donor_gain	1.0000
19:10106413:G:GC	donor_loss	1.0000
19:10106414:T:A	donor_loss	1.0000
19:10106496:CGCA:C	acceptor_loss	1.0000
19:10106497:GCAGT:G	acceptor_loss	1.0000
19:10106498:CA:C	acceptor_loss	1.0000
19:10106499:A:AG	acceptor_gain	1.0000
19:10106500:G:GC	acceptor_gain	1.0000
19:10106500:GT:G	acceptor_gain	1.0000
19:10106500:GTCCC:G	acceptor_gain	1.0000
19:10092671:T:TA	donor_gain	0.9900

AlphaMissense

2996 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
19:10092658:C:A	W448C	0.999
19:10092658:C:G	W448C	0.999
19:10092734:C:T	C423Y	0.999
19:10092745:C:A	W419C	0.999
19:10092745:C:G	W419C	0.999
19:10092747:A:G	W419R	0.999
19:10092747:A:T	W419R	0.999
19:10092773:C:G	C410S	0.999
19:10092773:C:T	C410Y	0.999
19:10092774:A:T	C410S	0.999
19:10093380:G:C	S397R	0.999
19:10093380:G:T	S397R	0.999
19:10093382:T:G	S397R	0.999
19:10093384:A:C	F396C	0.999
19:10093384:A:G	F396S	0.999
19:10092660:A:G	W448R	0.998
19:10092660:A:T	W448R	0.998
19:10092715:G:C	N429K	0.998
19:10092715:G:T	N429K	0.998
19:10092734:C:G	C423S	0.998
19:10092735:A:T	C423S	0.998
19:10092748:C:A	W418C	0.998
19:10092748:C:G	W418C	0.998
19:10092750:A:G	W418R	0.998
19:10092750:A:T	W418R	0.998
19:10092772:A:C	C410W	0.998
19:10092773:C:A	C410F	0.998
19:10093383:G:C	F396L	0.998
19:10093383:G:T	F396L	0.998
19:10093385:A:G	F396L	0.998

dbSNP variants (sampled 300 via entrez): RS1000134422 (19:10094621 G>A), RS1000143334 (19:10100444 C>T), RS1000270421 (19:10094442 G>A,C), RS1000522015 (19:10095972 G>A), RS1000836315 (19:10107201 G>T), RS1000867060 (19:10105519 A>G), RS1000896394 (19:10096929 TA>T), RS1000907135 (19:10102992 T>A,C), RS1001632745 (19:10102394 C>A,T), RS1001768624 (19:10102177 G>A), RS1001777895 (19:10107007 T>A), RS1001914776 (19:10106782 A>G), RS1002104177 (19:10103175 C>T), RS1002245662 (19:10102471 T>C), RS1002304897 (19:10106455 C>A,T)

Disease associations

OMIM: gene MIM:609336 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
brain aneurysm	Strong	Autosomal dominant
intracranial berry aneurysm	Supportive	Autosomal dominant

Mondo (2): intracranial berry aneurysm (MONDO:0016483), brain aneurysm (MONDO:0005291)

Orphanet (0):

HPO phenotypes

15 total (15 of 15 shown, HPO-id order):

HPO	Term
HP:0000822	Hypertension
HP:0001123	Visual field defect
HP:0001250	Seizure
HP:0001269	Hemiparesis
HP:0002138	Subarachnoid hemorrhage
HP:0002170	Intracranial hemorrhage
HP:0002326	Transient ischemic attack
HP:0002363	Abnormal brainstem morphology
HP:0002616	Aortic root aneurysm
HP:0002621	Atherosclerosis
HP:0002647	Aortic dissection
HP:0007029	Cerebral berry aneurysm
HP:0012246	Oculomotor nerve palsy
HP:0012518	Abnormal circle of Willis morphology
HP:0040197	Encephalomalacia

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST000189_31	Protein quantitative trait loci	4.000000e-07
GCST001859_12	Thiazide-induced adverse metabolic effects in hypertensive patients	3.000000e-06

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0004530	triglyceride measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D002532	Intracranial Aneurysm	C10.228.140.300.510.600; C14.907.055.635; C14.907.253.560.300

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

14 total (human), top 14 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	affects methylation, decreases methylation, increases expression	2
Nickel	increases expression	2
Valproic Acid	affects expression, increases methylation	2
di-n-butylphosphoric acid	affects expression	1
CGP 52608	affects binding, increases reaction	1
2-palmitoylglycerol	increases expression	1
bisphenol S	decreases methylation	1
jinfukang	affects cotreatment, increases expression	1
Resveratrol	affects cotreatment, decreases expression	1
Cisplatin	affects cotreatment, increases expression	1
Plant Extracts	affects cotreatment, decreases expression	1
Urethane	decreases expression	1
Cadmium Chloride	decreases expression	1
Okadaic Acid	increases expression	1

Cellosaurus cell lines

1 cell lines: 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B1EI	Abcam A-549 ANGPTL6 KO	Cancer cell line	Male

Clinical trials (associated diseases)

27 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT01444664	PHASE4	COMPLETED	Aneurysm Wall Histology Registry
NCT02037932	PHASE4	WITHDRAWN	Hydrogel Balloon Assisted Intracranial Aneurysm Coiling Registry
NCT00783523	PHASE1	COMPLETED	Influence of MMP on Brain AVM Hemorrhage
NCT00537134	Not specified	TERMINATED	Trial on Endovascular Aneurysm Management
NCT01557036	Not specified	TERMINATED	Aneurysm Study of Pipeline in an Observational Registry
NCT01558102	Not specified	COMPLETED	International Retrospective Study of Pipeline Embolization Device
NCT01716117	Not specified	COMPLETED	Safety and Effectiveness of an Intracranial Aneurysm Embolization System for Treating Large or Giant Wide Neck Aneurysms
NCT01975233	Not specified	COMPLETED	WEB French Observatory of the WEB Aneurysm Embolization System
NCT02345395	Not specified	UNKNOWN	Safety Study of Minimally Invasive Approaches to Unruptured Anterior Circulation Aneurysms
NCT02381522	Not specified	COMPLETED	Remote Ischemic Pre-conditioning in Subarachnoid Hemorrhage
NCT02435823	Not specified	COMPLETED	Safety Study of the PulseRider® in Patients Undergoing Treatment for Bifurcation Intracranial Aneurysms
NCT02687607	Not specified	COMPLETED	CLARYS: CLinical Assessment of WEB® Device in Ruptured aneurYSms
NCT03844334	Not specified	COMPLETED	CLinical EValuation of WEB 0.017 Device in Intracranial AneuRysms
NCT03852680	Not specified	UNKNOWN	Current Treatment Modalities for Wide Necked Intracranial Aneurysms
NCT03936647	Not specified	RECRUITING	The RISE Trial: A Randomized Trial on Intra-Saccular Endobridge Devices
NCT04439760	Not specified	COMPLETED	Superior Cervical Ganglion Block, Transcranial Doppler
NCT04553549	Not specified	COMPLETED	Safety and Feasibility of the Infinity Catheter for Radial Access
NCT05317169	Not specified	UNKNOWN	Aneurysm Genetic Risk in Patients With QIB Changes
NCT05626504	Not specified	UNKNOWN	Outcome Study of the Pipeline Embolization Device With Vantage Technology in Unruptured Aneurysms
NCT06456814	Not specified	RECRUITING	Epidemiological Insights Into the Formation, Progression, and Rupture of Intracranial Aneurysms: A Retrospective, Multi-Center Hospital-Based Study in China
NCT06541275	Not specified	ENROLLING_BY_INVITATION	Reduction in Volume and Prolonged Shrinkage of Brain Aneurysms After Combined Endovascular Interventions
NCT06689410	Not specified	RECRUITING	Multimodal Biocollection Linked to the French Register of Intracranial Aneurysms
NCT06761365	Not specified	RECRUITING	LUMENS-1 EU EFS CIP
NCT06798740	Not specified	RECRUITING	Post Market Registry Study of Intracranial Aneurysms Treated With Sugita Clipping Devices
NCT07143019	Not specified	RECRUITING	The Use of p48/64 MW HPC Flow Modulation Device in the Treatment of Wide-necked Intracranial Aneurysms
NCT07175519	Not specified	RECRUITING	Safety and Efficacy of Aneurysms Treated With Endovascular Devices
NCT07259018	Not specified	NOT_YET_RECRUITING	LUMENS-1 Canada Early Feasibility Study Clinical Investigation Plan